Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications - 09/11/20
, Iltefat Hamzavi, MD b, Indermeet Kohli, PhD b, Albert Wolkerstorfer, MD, PhD c, Henry W. Lim, MD b, Jung Min Bae, MD, PhD d, Harvey Lui, MD, FRCPC e, f, John E. Harris, MD, PhD g, Amit G. Pandya, MD h, Steven Thng Tien Guan, MBBS, MRCP i, Marwa Abdallah, MD j, Samia Esmat, MD k, Julien Seneschal, MD, PhD l, Reinhart Speeckaert, MD, PhD a, Lynda Grine, MSc, PhD a, Hee Young Kang, MD, PhD m, Noufal Raboobee, MD n, Leihong Flora Xiang, MD, PhD o, Marcel Bekkenk, MD, PhD c, Mauro Picardo, MD p, Alain Taieb, MD, PhD lAbstract |
Background |
Clinical photography is an important component of the initial assessment and follow-up of patients with vitiligo in clinical practice and research settings. Standardization of this photographic process is essential to achieve useful, high-quality, and comparable photographs over time.
Objective |
The aim is to develop an international consensus for a core set of recommendations for standardized vitiligo clinical photography.
Methods |
Based an international meeting of vitiligo experts, a standard operating procedure was developed for vitiligo photography in daily practice and research settings. This protocol was subsequently reviewed by 20 vitiligo experts until agreement was reached.
Results |
The resulting protocol includes a set of 10 and 15 photographs for clinical practice and research purposes, respectively. The photographic series are based on anatomic units included in the Vitiligo Extent Score. Furthermore, graphic representations of standardized positioning and suggestions for guidelines to standardize the process (background color, lighting, position marking, scales, materials, instruments) for both color and ultraviolet photographs are described.
Conclusions |
This consensus-based protocol for vitiligo photography will harmonize imaging for both clinical practice, translational research, and clinical trials. It can improve outcome assessment, foster multicenter collaboration, and promote better communication with patients regarding outcomes of treatment.
Il testo completo di questo articolo è disponibile in PDF.Key words : assessment, consensus, imaging, outcome, photography, research, standardized, vitiligo
Abbreviations used : UV, VES
Mappa
| Funding sources: The research activities of Dr van Geel are supported by the Scientific Research Foundation–Flanders (Fonds Wetenschappelijk Onderzoek [FWO] senior clinical investigator: 1831512N) and Leo Foundation grant (Leo Foundation project reference number LF16092). Supporting sources of organizing the meetings: Vitiligo International Patient Organizations Conference (VIPOC), European Society for Pigment Cell and Melanoma Research (ESPCR) and Associazione Ricerca e Informazione sulla Vitiligine (ARIV) for the Paris meeting, Global Vitiligo Foundation (GVF) for the Detroit meeting. |
|
| Disclosure: Dr van Geel is a consultant and/or investigator for Pfizer, Laboratoire Génévrier, and Incyte. Dr Hamzavi is an investigator for Estee Lauder, Ferndale, Unigen, Johnson and Johnson, Bayer, Allergan, and Incyte and is a consultant for Pfizer, Johnson and Johnson, and Bayer. Dr Kohli is an investigator for Ferndale, Estee Lauder, Unigen, Johnson and Johnson, Allergan, and Bayer and is a consultant for Pfizer, Johnson and Johnson, and Bayer. Dr Lim is a coinvestigator for Incyte. Dr Lui is an investigator/consultant for Pfizer, Johnson & Johnson, Novartis, LEO Pharma, and Sanofi-Genzyme. Dr Harris is a consultant and/or investigator for Pfizer, Genzyme/Sanofi, Stiefel/GlaxoSmithKline, Aclaris Therapeutics, Celgene, Incyte, Dermira, Rheos Medicines, Sun Pharmaceuticals, Leo Pharma, Villaris Therapeutics Inc, AbbVie, Janssen, TeVido BioDevices, EMD Serono, 3rd Rock Ventures, The Expert Institute, and BiologicsMD; has equity in TeVido Biodevices, Rheos, and Villaris Therapeutics, and is the scientific founder of Villaris Therapeutics. Dr Pandya is a consultant for Pfizer, is an investigator for Pfizer and Incyte, and serves on the board of directors of Clarify. Dr Raboobee is an advisory board member of Novartis, Janssen, and AbbVie. Drs Wolkerstorfer, Bae, Thng, Abdallah, Esmat, Seneschal, Speeckaert, Grine, Kang, Xiang, Bekkenk, Picardo, and Taieb have no conflicts of interest to declare. |
|
| IRB approval status: Reported at the local ethics committee at Ghent University Hospital, Belgium. |
Vol 83 - N° 6
P. 1639-1646 - dicembre 2020 Ritorno al numero
Articolo precedente
- Improved patient access and outcomes with the integration of an eConsult program (teledermatology) within a large academic medical center
- Rebecca F. Wang, John Trinidad, Jeffrey Lawrence, Llana Pootrakul, L. Arick Forrest, Kevin Goist, Edward Levine, Shalina Nair, Milisa Rizer, Andrew Thomas, Randell Wexler, Benjamin H. Kaffenberger
- Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study
- Eric Munger, Harry Choi, Amit K. Dey, Youssef A. Elnabawi, Jacob W. Groenendyk, Justin Rodante, Andrew Keel, Milena Aksentijevich, Aarthi S. Reddy, Noor Khalil, Jenis Argueta-Amaya, Martin P. Playford, Julie Erb-Alvarez, Xin Tian, Colin Wu, Johann E. Gudjonsson, Lam C. Tsoi, Mohsin Saleet Jafri, Veit Sandfort, Marcus Y. Chen, Sanjiv J. Shah, David A. Bluemke, Benjamin Lockshin, Ahmed Hasan, Joel M. Gelfand, Nehal N. Mehta
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?